Company Overview and News

 
Analyst Corner: Maintain ‘buy’ on KBL with revised TP of Rs 138

3h financialexpress
Karnataka Bank (KBL) reported a mixed Q2FY19 performance. PAT at Rs 1.1 billion (up 20% Y-o-Y) was supported by lower credit cost and controlled opex (down >2% YoY), even while core profitability was muted. While steady asset quality, lower SMA-2 accounts and sustained loan growth (up >21% YoY) was encouraging, operationally it was a soft quarter with pressure on NIMs, softer fee income (albeit improving) and muted CASA growth (SA up <10% YoY).
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

9h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
Karnataka Bank aims to reduce gross NPAs to 4%

2018-10-12 moneycontrol
Karnataka Bank on October 12 said it aims to reduce gross NPAs (non-performing assets) to four percent.
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
The Karnataka Bank Limited - Financial Result Updates

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
Share market LIVE updates: Sensex, Nifty to remain cautious ahead of macro-data release; HUL, Yes Bank in focus

2018-10-12 financialexpress
Share market live: Sensex and Nifty — the benchmark indices of the Indian stock market — are likely to start on a tepid note on Friday on caution ahead of major macro-economic data release later during the day. SGX Nifty futures were trading 57.50 points or 0.56% higher at 10,337 points on the Singapore Exchange during early morning deals in today, indicating a positive start for the NSE Nifty 50 index.
YESBANK 513010 SPXCF KTKBANK HINDUNILVR 532648 YYBKY TTNQY S68 532652 SPXCY 532540 TATASPONGE 500696 TCS

 
HUL, 9 others to throw light on Q2 show

2018-10-11 thehindubusinessline
Ten firms will declare their quarterly performance on Friday. These are 3i Infotech, Atishay, Biopac India Corporation, Integrated Capital Services, i-Power Solutions, Karnataka Bank, Quintegra, Rasoi, and Tata Sponge Iron. Focus will be on Hindustan Unilever, as that will give a clear picture on the performance of FMCG companies as well as the current economic activity. Most analysts expect HUL’s revenue to grow about 15 per cent y-o-y and net profit about 25 per cent.
532652 513010 532330 ICSL 539149 TATASPONGE 500696 KTKBANK HINDUNILVR BIOPAC

 
The Karnataka Bank Limited - Press Release

2018-10-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

2018-09-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

2018-09-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

 
The Karnataka Bank Limited - Press Release

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...